News – Overland Park Peptides (ARL)

abdominal adiposity Sep 11, 2026 Retatrutide vs Tirzepatide for Visceral Fat ReductionRetatrutide's glucagon receptor agonism may enhance visceral fat loss compared to tirzepatide, but direct evidence is lacking. This article reviewsRead article

CJC-1295 stacking Sep 09, 2026 Retatrutide Muscle Loss vs Tirzepatide: Glucagon RoleRetatrutide's glucagon component may reduce muscle loss during rapid weight loss compared to tirzepatide, but phase 2 evidence is preliminary....Read article

dual agonist Aug 28, 2026 Retatrutide vs Tirzepatide for Type 2 Diabetes RemissionRetatrutide and tirzepatide may influence type 2 diabetes remission through distinct receptor actions. This article compares their mechanisms, evidenceRead article

GLP-1 sleep effects Aug 28, 2026 Retatrutide vs Tirzepatide for Sleep Quality and Circadian RhythmRetatrutide and tirzepatide differ by one receptor. Does that extra glucagon activity change sleep or circadian rhythm during weight loss?...Read article

GLP-1 lipedema Aug 26, 2026 Retatrutide for Lipedema-Related Weight Loss: Triple-Agonist vs TirzepatideRetatrutide and tirzepatide are incretin-based peptides studied for weight loss, but neither has been tested in lipedema. This article reviews...Read article

craving control peptides Aug 21, 2026 Retatrutide and Food Noise: Glucagon Effects vs TirzepatideRetatrutide adds glucagon receptor agonism to tirzepatide's dual incretin action. Early data suggest stronger craving control, but food noise researchRead article

GLP-1 pill transition Aug 19, 2026 Tirzepatide vs. Retatrutide for GLP-1 Pill TransitionSwitching from injectable GLP-1 therapy to an oral pill is a major metabolic event. Tirzepatide and retatrutide have distinct receptor...Read article

GLP-1 alcohol use disorder Aug 14, 2026 Retatrutide and Alcohol Cravings: Triple-Agonist vs TirzepatideRetatrutide and tirzepatide both show early signals for reducing alcohol cravings, but no head-to-head human data exist. This article reviews...Read article

alcohol cravings Aug 12, 2026 Retatrutide and Alcohol Cravings: Can the Triple-Agonist Outperform Tirzepatide?Retatrutide, a triple-agonist peptide, is being explored for alcohol cravings, but it lacks FDA approval. Could it outperform tirzepatide? Evidence...Read article